Study of NKX019 for immune diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have one of these conditions: scleroderma, myositis, vasculitis, or rheumatoid arthritis, and it is active despite prior treatments.
- Your kidney function is at least moderately good (eGFR 45 or higher).
- You have not had a prior organ or stem cell transplant.
- You do not have active serious infections, recent major heart problems, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether a new type of immune cell (CAR NK) can treat two conditions: antisynthetase antibody syndrome (a rare autoimmune disease) and rheumatoid arthritis. It's for people whose current treatments haven't worked well enough.
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.